- Home
- SEPN vs AUPH Comparison
SEPN vs AUPH Comparison
Compare SEPN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- AUPH
- Stock Information
- Founded
- SEPN 2022
- AUPH 1993
- Country
- SEPN United States
- AUPH Canada
- Employees
- SEPN N/A
- AUPH N/A
- Industry
- SEPN
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SEPN
- AUPH Health Care
- Exchange
- SEPN NYSE
- AUPH Nasdaq
- Market Cap
- SEPN 1.0B
- AUPH 1.0B
- IPO Year
- SEPN 2024
- AUPH 1999
- Fundamental
- Price
- SEPN $22.53
- AUPH $8.12
- Analyst Decision
- SEPN
- AUPH Strong Buy
- Analyst Count
- SEPN 0
- AUPH 3
- Target Price
- SEPN N/A
- AUPH $10.33
- AVG Volume (30 Days)
- SEPN 399.2K
- AUPH 1.3M
- Earning Date
- SEPN 11-26-2024
- AUPH 11-07-2024
- Dividend Yield
- SEPN N/A
- AUPH N/A
- EPS Growth
- SEPN N/A
- AUPH N/A
- EPS
- SEPN N/A
- AUPH N/A
- Revenue
- SEPN $838,000.00
- AUPH $220,361,000.00
- Revenue This Year
- SEPN N/A
- AUPH $36.52
- Revenue Next Year
- SEPN N/A
- AUPH $19.02
- P/E Ratio
- SEPN N/A
- AUPH N/A
- Revenue Growth
- SEPN N/A
- AUPH 38.72
- 52 Week Low
- SEPN $18.62
- AUPH $4.71
- 52 Week High
- SEPN $26.34
- AUPH $10.05
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- AUPH 62.64
- Support Level
- SEPN N/A
- AUPH $8.06
- Resistance Level
- SEPN N/A
- AUPH $8.70
- Average True Range (ATR)
- SEPN 0.00
- AUPH 0.34
- MACD
- SEPN 0.00
- AUPH 0.07
- Stochastic Oscillator
- SEPN 0.00
- AUPH 63.74
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.